The Femtech sector is developing fast with impressive potential as founders are normalizing taboo topics. There is more innovation around menopause tech, pelvic health care, chronic disease management, sexual wellness and education, and urinary care. The global Femtech market size is estimated to reach around $75B by 2026, growing at a 13.3% compound annual growth rate (CAGR), according to research published by Arizton Advisory & Intelligence.
Dynamics underlying Femtech are also accelerating as company formation, enterprise value, and funding are surging. In 2021, FemTech startups have raised $2.5B in VC investment, up 42x vs. 2010. Between 2016 and 2021, Femtech startups have raised $6.9B. Last year, 58% of total investment corresponds to rounds above $100M, like Ro Health ($500M), Lyra Health ($200M), Maven Clinic ($110M), among others. The US is the undisputed FemTech leader. In 2021, 81% of total investment corresponds to VC investment in the US, 13% to Europe, and 5% to Asia.
Today, Femtech startups have a combined enterprise value of $42B, a 10x increase since 2016. Ro Health is the most valued Femtech company so far ($7B), followed by Lyra Health ($5.9B) and Progyny ($3.1B).
The term “Femtech” was first coined in 2016 by entrepreneur Ida Tin. In the course of just a few years, it has grown to encompass a range of technology-enabled, consumer-centric products and solutions. Today, the global Femtech market is represented by 500+ startups and scaleups founded after 1990, while in 2010 there were only 69 startups.
Bridgehead: Bridgehead provides European start-ups and scale-ups with individualized support in growing their validated businesses beyond their home markets.
Catapult: Catapult boosts the development and publicity of high-potential European health start-ups, exposing Biotech, MedTech, and Digital Health start-ups to high-quality experts and health industry leaders.
Patient Innovation Bootcamp: Patient Innovation Bootcamp supports the development and launch of innovative solutions created by people directly affected by health conditions, such as patients and caregivers.
Reactor Bootcamp: In partnership with GE Healthcare, Reactor Bootcamp provides a customized path for start-ups so they can find their product-market fit, accelerate early adoption and get prepared for partnership building.
Start-ups Meet Pharma: A challenge-based acceleration programme connecting key pharma partners in Europe with startups at the forefront of technology innovation.
Start-ups Meet Healthcare Providers: This challenge-based programme brings together healthcare providers posing specific problems that hinder their effective and best possible provision of care and start-ups representing solutions for the selected challenges.
User Validation Labs: This programme was created to connect start-ups with user validation labs that can work with them to organize and execute a validation study of their innovation.
Women Entrepreneurship Bootcamp: The Women Entrepreneurship Bootcamp connects early-stage, women-led or co-led healthcare start-ups to an unparalleled network of mentors in order to nurture and support rapid growth.
Wild Card: Wild Card calls for all inventors, creators and self-starters to solve this year's two challenges: Advancing early diagnosis and screening of cancer and improving the prevention, detection, diagnosis, and treatment to fight mental disorders.
Latest healthtech and biotech deals
The largest from last week:
🇺🇸 DNAnexus, a bioinformatics company, raised $200M at $600M valuation. DNAnexus has a platform that puts massive sets of genomic data into the cloud so it can be accessed and analyzed by researchers who may be unable to process that volume onsite.
🇦🇺 Saluda Medical, a medical device company specializing in neuromodulation therapies which use closed-loop technologies to treat debilitating neurological disorders, raised $125M.
🇬🇧 Microbiotica, a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers, raised £50M in Series B funding.
Other notable deals from around the globe:
🇨🇳 InxMed, a biotech company developing cancer therapies, raised $50M in Series B.
🇳🇱 Scenic Biotech, a developer of genomics and immunotherapy technologies created to unlock genetic suppressors, raised €28M in Series A.
📖 We revamped the left-side bar in the dealroom.co web app. Now you can easily navigate across our key categories: Companies, Job Board, Stats & Insights, Investors, Transactions, People, and More organizations.
This is Dealroom's weekly health newsletter. Get more industry-specific intelligence on the evolving world of healthtech and biotech, emerging trends, and game-changing startups. Delivered on Thursdays.
Dealroom.co, Cornelis Dirkszstraat 27-2, 1056 TP, Amsterdam, The Netherlands
%20(1).png?upscale=true&width=1200&upscale=true&name=unnamed%20(7)%20(1).png)
